Arrowhead Research Corporation (NASDAQ:ARWR) : Investors lapped up stocks on upticks to the tune of $0.02 million in the Wednesdays trading session. The trading value on downticks was comparatively at $0 million and the uptick to downtick ratio of 5 indicates continuous buying by the bulls. The net money flow into the stock was $0.02 million. Upticks saw transactions worth $0.01 clearly indicating buying by large investors. The total money flow for block trades stood at $0.01 million, which is a positive for the stock in the long-term. Arrowhead Research Corporation (NASDAQ:ARWR) fell $0.01 during the day at $5.3, a drop of -0.19% over the previous days close. However, for the week, the stock is -3.11%, compared to the previous week.
In an insider trading activity,The officer (Chief Financial Officer) of Arrowhead Research Corp, Myszkowski Kenneth Allen sold 23,347 shares at $6.13 on December 30, 2015. The Insider selling transaction had a total value worth of $143,117. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. Currently the company Insiders own 3.9% of Arrowhead Research Corporation shares according to the proxy statements. Institutional Investors own 34.15% of Arrowhead Research Corporation shares.
The company shares have dropped -23.60% from its 1 Year high price. On Sep 24, 2015, the shares registered one year high at $9.36 and the one year low was seen on Feb 11, 2016. The 50-Day Moving Average price is $5.69 and the 200 Day Moving Average price is recorded at $5.07. Arrowhead Research Corporation (NASDAQ:ARWR): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $5.37 and $5.25 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $5.46. The buying momentum continued till the end and the stock did not give up its gains. It closed at $5.41, notching a gain of 1.88% for the day. The total traded volume was 351,782 . The stock had closed at $5.31 on the previous day.
Arrowhead Research Corporation develops drugs to treat intractable diseases by silencing the genes that cause them. Using the broadest portfolio of RNA chemistries and efficient modes of delivery, the Companys therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. The Companys drug candidate in clinical development is ARC-520, which is designed to treat chronic hepatitis B infection by inhibiting the production of all HBV gene products. The goal is to reverse the immune suppression that prevents the body from controlling the virus and clearing the disease. Its second clinical candidate is ARC-AAT, a treatment for a rare liver disease associated with a genetic disorder that causes alpha-1 antitrypsin deficiency.